Mersana Therapeutics, a biopharmaceutical company developing its Fleximer® antibody-drug conjugate (ADC) platform and pipeline of small molecule Fleximer conjugates, today announced its involvement in two upcoming conferences being held during February.

Michael A. Metzger, Executive Vice President and Chief Operating Officer, will attend the Oncology Partnering and Deal Making Conference in Las Vegas, February 25-26, 2013. The conference is part of the Novel Cancer Therapeutics Summit, hosted by Global Technology Community (GTC).

Timothy B. Lowinger, Ph.D., Chief Scientific Officer, will present ʺNext Generation ADCs: Higher Drug Loading, Alternative Payloads and Alternative Targeting Moietiesʺ at 3:00 p.m. on February 27, 2013 at the ADC Development and Production Conference being held at the Hyatt Regency in Huntington Beach, Calif. The conference is part of Biopharmaceutical Development & Production Week, hosted by IBC Life Sciences.

About Mersana

Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes. Utilizing its proprietary conjugation technology, which is comprised of the Fleximer® polymer and a broad array of customizable linker chemistries, Mersana is developing its next-generation antibody-drug conjugate (ADC) platform with superior properties not found with other ADC technologies. Mersana is currently working with a number of top Pharma companies to develop next generation Fleximer-ADCs and most recently announced a $270 million collaboration with Endo Pharmaceuticals in March, 2012. The company is also advancing its own pipeline of next-generation drugs with best-in-class potential to address unmet needs and improve patient outcomes in multiple oncology indications. 

Media Contact

 MacDougall Biomedical Communications
 Jennifer Conrad
 781-235-3060
 jconrad@macbiocom.com